Beyond GLP-1Rs: Emerging Targets Poised to Gain Share of Obesity Market

Why It Matters

The rapid expansion of non‑GLP‑1R obesity drugs creates a multi‑billion‑dollar growth runway and reduces industry reliance on a single drug class, reshaping competitive dynamics.

Key Takeaways

• Non‑GLP‑1R obesity drugs projected to hit $15.5 bn by 2031.
• Calcitonin receptor drugs forecast to capture $5.43 bn, 35% of non‑GLP‑1R market.
• Eli Lilly’s eloralintide expected to lead CR segment with $3.4 bn sales.
• Market growth driven by 110.8% CAGR after 2028 product launches.
• Diversification reduces reliance on GLP‑1R class, expanding treatment options.

Pulse Analysis

The global obesity drug market is on a trajectory that rivals the fastest‑growing therapeutic categories. Forecasts from GlobalData project total sales of $172.6 bn by 2031, up 139% from $72.2 bn in 2026, driven largely by GLP‑1R agonists such as Wegovy and Zepbound. While these agents currently command the lion’s share, the sheer scale of the market—over 100 million adults in the United States alone—creates room for additional mechanisms to capture value as payers and physicians seek broader treatment portfolios.

Beyond the GLP‑1R class, non‑GLP‑R candidates are poised for explosive growth. Sales for drugs targeting alternative pathways are expected to rise from a modest $310 m in 2026 to roughly $15.5 bn by 2031, reflecting a compound annual growth rate of 110.8% after the first launches in 2028. Calcitonin receptor (CR) agents will dominate this segment, projected at $5.43 bn, or 35% of non‑GLP‑1R revenue. Eli Lilly’s eloralintide and Novo Nordisk’s cagrilintide are slated to lead, together accounting for more than $4 bn.

The shift toward diversified mechanisms signals a strategic hedge for the industry’s biggest players. By expanding into CR and melanocortin‑4 pathways, companies reduce dependence on a single drug class and mitigate regulatory or safety risks that could affect GLP‑1R pipelines. For investors, the emerging segment offers a new frontier of high‑margin growth, while clinicians gain additional options to tailor therapy for patients who do not respond to or tolerate GLP‑1R agents. As the market matures, competition is likely to intensify, driving innovation and potentially lowering prices.